Author

Maria Petrecz

Observed name: Maria L. Petrecz

Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), University of Louisville, University of Pennsylvania

OpenAlex ID: A5035000320

A Prospective, Multicenter Study of Caspofungin for the Treatment of Documented Candida or Aspergillus Infections in Pediatric Patients

2009 · Theoklis E. Zaoutis, Hasan S. Jafri, et al. · PEDIATRICS · 106

Safety Experience With Caspofungin in Pediatric Patients

2009 · Theoklis Zaoutis, Thomas Lehrnbecher, et al. · The Pediatric Infectious Disease Journal · 38

Immunogenicity, Safety, and Tolerability of a Hexavalent Vaccine in Infants

2015 · Gary S. Marshall, Gregory L. Adams, et al. · PEDIATRICS · 32

Concomitant Use of the 3-Dose Oral Pentavalent Rotavirus Vaccine With a 3-Dose Primary Vaccination Course of a Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Inactivated Polio-Haemophilus influenzae Type b Vaccine

2009 · Max Ciarlet, Su He, et al. · The Pediatric Infectious Disease Journal · 30

Lot-to-lot Consistency, Safety, Tolerability and Immunogenicity of an Investigational Hexavalent Vaccine in US Infants

2016 · Stanley L. Block, Nicola P. Klein, et al. · The Pediatric Infectious Disease Journal · 25

Concomitant administration of hepatitis A vaccine with measles/mumps/rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children

2013 · Robert J Yetman, Julie S Shepard, et al. · Human Vaccines & Immunotherapeutics · 19

Analysis of safety data in children after receiving two doses of ProQuad® (MMRV)

2014 · Stephanie O. Klopfer, Jon E. Stek, et al. · Vaccine · 14

Using the power law model to predict the long-term persistence and duration of detectable hepatitis A antibody after receipt of hepatitis A vaccine (VAQTA™)

2021 · Jason C. Martin, Maria L. Petrecz, et al. · Vaccine · 13

Kartsonis NA, Ngai AL, A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients

2009 · TE Zaoutis, Jafri Hs, et al. · 7

Concomitant use of VAQTA® with PedvaxHIB® and Infanrix® in 12 to 17 month old children

2015 · Maria Petrecz, Keith P Ramsey, et al. · Human Vaccines & Immunotherapeutics · 6

Safety and immunogenicity of VAQTA® in children 12-to-23 months of age with and without administration of other US pediatric vaccines

2018 · Maria Petrecz, Camilo J. Acosta, et al. · Human Vaccines & Immunotherapeutics · 4

Immunogenicity and Safety of an Investigational Hexavalent Vaccine Against Diphtheria, Tetanus, Pertussis (DTaP5), Polio (IPV), H. Influenzae Type b (Hib; PRP-OMPC), and Hepatitis B (HepB) Administered Concomitantly with RV5 and PCV-13 in US Infants

2016 · Stanley L Block, Gary Marshall, et al. · PEDIATRICS · 2

1112A Phase III Study of the Safety, Tolerability and Immunogenicity of an Investigational Combination Vaccine against Diphtheria, Tetanus, Pertussis (DTaP5), Polio (IPV), Haemophilus influenzae type b (Hib; PRP-OMPC), and Hepatitis B (HepB) in US Infants

2014 · Gary S. Marshall, Gregory Adams, et al. · Open Forum Infectious Diseases

Works count: 13

Citation count: 296

H-index: 8

I10-index: 8